These findings were also confirmed in vivo, where the administration of BACE1/2 inhibitors results in a decreased tumor volume of xenotransplanted glioblastoma and lung adenocarcinoma and impacts negatively on tumor vascularization [63]. This evidence concerns the gene BACE1 and neoplasm.